U.S. Energy Services Stock News

Check Point Software Technologies (CHKP) recently released its second-quarter earnings with positive year-over-year growth, highlighting increased revenues and net income. The market, mainly focused on earnings, remained relatively flat, with CHKP's share price movements echoing this broader market trend. The company's ongoing share buyback program likely added weight to investor sentiment during this period. Moreover, the strategic partnership announcement with MetTel and the executive...

As the U.S. stock market navigates a landscape of fluctuating indices and economic indicators, investors are closely monitoring the Federal Reserve's interest rate decisions and major tech earnings reports, which have recently driven optimism despite intermittent setbacks. In this dynamic environment, identifying high growth tech stocks that align with strong corporate earnings and favorable economic data can be an effective strategy for those looking to expand their portfolios amidst...

As the U.S. stock market experiences a mix of optimism and caution, with major indices like the S&P 500 and Nasdaq Composite recently hitting record highs, investors are keenly observing corporate earnings and waiting for the Federal Reserve's decision on interest rates. In this environment, identifying stocks that may be trading below their estimated value can provide opportunities for investors looking to capitalize on potential market inefficiencies.

As the U.S. stock market experiences a period of cautious optimism, with major indices like the S&P 500 and Nasdaq Composite showing gains ahead of key Federal Reserve announcements and tech earnings reports, investors are keenly observing the influence of economic data on market movements. In this environment, growth companies with high insider ownership stand out as potentially strong candidates for investment consideration; their leadership's vested interest often signals confidence in...

As the U.S. stock market navigates a landscape marked by anticipation of Federal Reserve interest rate decisions and major tech earnings, investors are exploring diverse opportunities for growth. Penny stocks, often associated with smaller or emerging companies, continue to capture attention due to their affordability and potential for significant returns. Despite being considered an outdated term, these stocks can still offer valuable prospects when backed by strong financials and solid...

As the U.S. market navigates a landscape marked by cautious optimism surrounding corporate earnings and economic growth, investors are keenly watching the Federal Reserve's interest rate decisions and their potential impact on small-cap stocks. In this environment, identifying promising opportunities often involves seeking out companies that demonstrate resilience and innovation amidst broader market fluctuations.

As the U.S. stock market experiences fluctuations, with major indices like the S&P 500 and Nasdaq Composite showing modest gains ahead of significant earnings reports and a Federal Reserve interest rate decision, investors are keenly observing corporate performances and economic indicators. In such an environment, dividend stocks can offer stability and income potential, making them attractive to those looking for reliable returns amidst market uncertainties.

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Key Insights Significantly high institutional ownership implies Blaize Holdings' stock price is sensitive to their...

Nucor (NYSE:NUE) has had a great run on the share market with its stock up by a significant 18% over the last three...

Praxis Precision Medicines recently announced that the FDA granted Breakthrough Therapy Designation (BTD) for relutrigine in pediatric patients with SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs), based on strong Phase 2 study results showing substantial seizure reduction. This recognition underscores relutrigine’s potential to address significant unmet needs in a population with limited effective treatment options and a history of challenging disease management. We’ll...

On July 21, 2025, LexinFintech Holdings announced that its Board of Directors had authorized a share repurchase program of up to US$50 million, valid over the next 12 months. This move is often interpreted by the market as a sign that management sees value in the company's shares and is committed to returning capital to shareholders. We will explore how the new buyback program could influence LexinFintech's investment case and shareholder value priorities. Find companies with promising cash...

Virtus Investment Partners recently reported its second quarter 2025 results, highlighting US$210.53 million in revenue and a significant increase in net income to US$42.37 million, alongside continued execution of its substantial share buyback program. An interesting point was that the company's net income and earnings per share grew despite a year-over-year decline in revenue, supported by management's active share repurchases. Next, we'll explore how Virtus Investment Partners' rising...

Ellington Financial recently announced preliminary earnings guidance for the second quarter ended June 30, 2025, estimating net income per share between US$0.43 and US$0.47. This early disclosure of financial performance signals the company’s focus on transparency and may prompt investor attention to its evolving outlook. We'll look at how Ellington Financial's updated earnings forecast impacts its investment narrative around loan portfolio growth and debt refinancing. The end of cancer?...

Earlier this month, Premier entered into a national group purchasing agreement with Beyond Air, Inc., granting its members access to special pricing and terms for the LungFit PH system and NO2 Smart Filters used in respiratory care. This partnership brings innovative nitric oxide technology directly to Premier’s network, potentially supporting greater access to advanced therapeutic gases for critically ill patients. We’ll assess how the expanded access to Beyond Air’s technology may impact...

Earlier this month, Disc Medicine reported positive feedback from the U.S. FDA regarding its planned New Drug Application submission for bitopertin as a potential treatment for erythropoietic protoporphyria (EPP), targeting an October 2025 filing under the accelerated approval pathway. This milestone highlights bitopertin’s potential to address a significant unmet need for EPP patients, who currently have extremely limited disease-modifying treatment options. We'll assess how this regulatory...

While H.B. Fuller Company ( NYSE:FUL ) might not have the largest market cap around , it saw a double-digit share price...

O-I Glass reported second quarter 2025 earnings, revealing sales of US$1.71 billion and a net loss of US$5 million, reversing from a net income of US$57 million during the same period last year. This shift from profit to loss highlights operational headwinds or softer demand, raising questions about the company’s resilience in the current market environment. We'll assess how the swing to a net loss impacts O-I Glass’s investment narrative focused on sustainable packaging growth and...

Dynex Capital recently reported a net loss of US$13.61 million for the second quarter and US$16.68 million for the first half of 2025, with losses also reflected on a per share basis. The company has filed a shelf registration covering multiple types of securities, a move that may signal preparations for future capital raises amid ongoing profitability headwinds. We'll explore how the shelf registration, in the context of recent quarterly losses, shapes Dynex Capital's current investment...

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

Strategic Education released its latest earnings results last Wednesday before market hours, with analysts having anticipated a 3.5% year-on-year revenue increase for the quarter, a slower pace compared to the same period last year. An interesting aspect of this event is that, despite the slowdown in expected revenue growth, analyst estimates remained steady in the month leading up to the announcement, pointing to continued confidence in the company’s outlook. With analyst consensus having...

Accel Entertainment recently attracted increased analyst optimism and positive brokerage sentiment, highlighted by improvements in key ranking metrics and technical momentum as the stock approached its 52-week high. This shift has sparked heightened interest from trend-focused investors who are responding to both bullish forecasts and the company’s favorable market positioning. We'll explore how growing analyst confidence and technical momentum could influence Accel Entertainment's evolving...

In July 2025, CG Oncology announced that a Delaware jury unanimously ruled in its favor in a lawsuit brought by ANI Pharmaceuticals over royalties related to its investigational bladder cancer therapy, cretostimogene grenadenorepvec. This outcome means CG Oncology is no longer required to pay any future royalties or damages to ANI Pharmaceuticals, eliminating a financial overhang tied to its lead therapeutic candidate. We’ll explore how the company’s removal of future royalty obligations...